Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma

Jeremy Abramson, MD, Massachusetts General Hospital, Boston, MA, discusses the results of a Phase II trial (NCT02505269) assessing brentuximab vedotin (BV) in combination with doxorubicin and dacarbazine (AD) for the treatment of limited-stage classical Hodgkin lymphoma (cHL). BV-AD was associated with excellent complete response (CR) and progression-free survival (PFS) rates, and a reduced toxicity profile. Dr Abramson also highlights an ongoing Phase II trial (NCT03646123) assessing the addition of nivolumab to this treatment regimen in limited-stage HL, which has reported a benefit with respect to CR and PFS rates in interim analyses. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.